F

Fate Therapeutics
D

FATE

1.69000
USD
0.04
(2.42%)
Market Closed
Volume
117,464
EPS
-2
Div Yield
-
P/E
-1
Market Cap
192,481,423
OverviewSignalsIdeasNews
Related Instruments
    B
    BLUE
    -0.69000
    (-7.52%)
    8.49000 USD
    C
    CLLS
    0.00000
    (0.00%)
    1.58000 USD
    C
    CRSP
    0.360
    (0.89%)
    40.720 USD
    E
    EDIT
    -0.01000
    (-0.75%)
    1.32000 USD
    N
    NTLA
    0.120
    (0.99%)
    12.190 USD
    S
    SGMO
    0.17500
    (7.56%)
    2.49000 USD
    V
    VYGR
    0.06000
    (1.05%)
    5.76000 USD
    More
News

Title: Fate Therapeutics

Sector: Healthcare
Industry: Biotechnology
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.